Patients’ characteristics (n=101)
| Characteristic | Value |
| Sex (n) | |
| Male | 55 |
| Female | 46 |
| Age (years) | |
| Median (range) | 69.47 (26.48–91.26) |
| ECOG Performance Status (n) | |
| 0 | 69 |
| 1 | 22 |
| 2 | 9 |
| 3 | 1 |
| 4 | 0 |
| 5 | 0 |
| Hypertension (n) | |
| Yes | 62 |
| No | 39 |
| Diabetes mellitus (n) | |
| Yes | 13 |
| No | 88 |
| Follow-up (months) | |
| Mean (SD) | 34.56 (±14.70) |
| Median (range) | 31.97 (2.53–75.99) |
| Location (n) | |
| Choroidal | 90 |
| Ciliochoroidal | 11 |
| Affected eye (n) | |
| Left | 56 |
| Right | 45 |
| Affected eye segments (n)14 | |
| 3 affected eye segments | 44 |
| >3 affected eye segments | 57 |
| Location specifications (n) | |
| Juxtapapillary | 45 |
| Initial characteristics (n) | |
| Subretinal fluid at diagnosis | 71 |
| Macular oedema at diagnosis | 9 |
| Orange pigment at diagnosis | 16 |
| Conversion from nevus | 9 |
| Tumour thickness (mm) | |
| Mean (SD) | 5.99 (±3.75) |
| Median (range) | 5.03 (0.87–15.52) |
| Largest basal diameter (mm) | |
| Mean (SD) | 11.06 (±4.03) |
| Median (range) | 10.00 (3.00–20.00) |
| Gross tumour volume (cm³) at diagnosis | |
| Mean (SD) | 0.60 (± 0.57) |
| Median (range) | 0.42 (0.18–2.60) |
| Planning target volume (cm³) | |
| Mean (SD) | 1.75 (± 1.18) |
| Median (range) | 1.34 (0.33–5.66) |
| Tumor size (COMS29) (n) | |
| Small | 30 |
| Medium | 38 |
| Large | 33 |
| Clinical Stage Group (AJCC Cancer Staging Manual 8th ed, 201730) (n) | |
| I | 38 |
| IIA | 31 |
| IIB | 14 |
| IIIA | 12 |
| IIIB | 6 |
| T category (AJCC Cancer Staging Manual 8th ed, 201730) (n) | |
| T1 | 38 |
| T2 | 33 |
| T3 | 18 |
| T4 | 12 |
| Endoresection after radiotherapy (n) | |
| Yes | 19 |
| No | 82 |
| Complications (n) | |
| Cataract progression | 71 |
| Neovascular glaucoma | 21 |
| Rubeosis iridis | 24 |
| Keratopathy | 40 |
| Macular oedema | 20 |
| Hyphema | 3 |
| Vitreous haemorrhage | 12 |
| Retinopathy | 14 |
| Optic neuropathy | 8 |
| Radiation scarring | 32 |
| Sicca symptoms | 18 |
| Overall survival (n) | |
| Death | 20 |
| Disease-specific death | 8 |
| Local recurrence | 6 |
| Metastasis | 12 |
| Enucleation | 7 |
AJCC, American Joint Committee on Cancer; COMS, Collaborative Ocular Melanoma Study; ECOG, Eastern Cooperative Oncology Group; n, number of patients; SD, standard deviation.